Registration - In-house Corporation

Amgen Canada Inc. / Brian Heath, General Manager & Vice-President

Registration Information
In-house Corporation name: Amgen Canada Inc.
Responsible Officer Name: Brian Heath, General Manager & Vice-President 
Responsible Officer Change History
Initial registration start date: 2007-05-16
Registration status: Active
Registration Number: 944822-15332
Associated Communications

Total Number of Communication Reports: 115

Monthly communication reports in the last 6 months: 4

Version 1 of 21 (2007-05-16 to 2007-12-11)

Version 1 of 21 (2007-05-16 to 2007-12-11) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Information about Responsible Officer and Corporation

Corporation: Amgen Canada Inc.
6755 Mississauga Road
Mississauga, ON  L5N 7Y2
Canada
Telephone number: 905-285-3150
Responsible officer name and position during the period of this registration: Daniel Billen, Vice President & General Manager  
Description of activities: Scientific affairs; Commercial operations; and administrative activities in biotechnology sector.
 
The client is a subsidiary of the following parent companies: Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA
United States of America 91320-1799

Coalition The corporation is not a member of a coalition.
Subsidiary: The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking.
Other direct interests The corporation's activities are not controlled or directed by another person or organization with a direct interest in the outcome of this undertaking.
 
Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? No
 

B. Lobbyists Employed by the Corporation

Name: Paul Moen
Position title: Director, Federal Government Affairs
Public offices held: Yes
 
Name: Geoff Sprang
Position title: Director, Corporate Affairs
Public offices held: No
 

C. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Finance Canada (FIN), Health Canada (HC), Industry Canada, Patented Medicine Prices Review Board (PMPRB)
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Meetings, Telephone calls, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Health, Industry, Intellectual Property, Science and Technology, Taxation and Finance
 
Subject Matter: Retrospective: - Health Canada re: Food and Drug Act, Regulations and Guidance- Health Canada re: Patented Medicines Notice of Compliance (NOC) Regulations- Health Canada re: Progressive Licensing Framework Policy- Health Canada re: Subsequent Entry Biologics Policy- Health Canada re: National Pharmaceutical Strategy- Health Canada re: Canadian Agency for Drugs and Technology in Health, Common Drug Review, Regulatory Approval, Health Canada- Food and Drug Act- Industry Canada re: Patent Act, Regulations and Guidance (including those on Patented Medicines Price Review Board)- Innovation Strategy Industry Canada re: "Mobilizing Science and Technology to Canada's Advantage"
Subject Matter: Prospective: - Health Canada re: Food and Drug Act, Regulations and Guidance- Health Canada re: Patented Medicines Notice of Compliance (NOC) Regulations- Health Canada re: Progressive Licensing Framework Policy- Health Canada re: Subsequent Entry Biologics Policy- Health Canada re: National Pharmaceutical Strategy- Health Canada re: Canadian Agency for Drugs and Technology in Health, Common Drug Review, Regulatory Approval, Health Canada- Food and Drug Act- Industry Canada re: Patent Act, Regulations and Guidance (including those on Patented Medicines Price Review Board)- Innovation Strategy Industry Canada re: "Mobilizing Science and Technology to Canada's Advantage"
 
Details Regarding the Identified Subject Matter
Categories Description
Policy or Program Health Canada re: Canadian Agency for Drugs and Technology in Health (Common Drug Review)
Legislative Proposal Health Canada re: Food and Drug Act
Bill or Resolution Health Canada re: Food and Drug Act
Policy or Program Health Canada re: Food and Drug Act Guidance
Regulation Health Canada re: Food and Drug Act Regulations
Policy or Program Health Canada re: National Pharmaceutical Strategy
Policy or Program Health Canada re: National Pharmaceutical Strategy, Regulatory Approval, Health Canada
Policy or Program Health Canada re: Progressive Licensing Framework Policy
Policy or Program Health Canada re: Subsequent Entry Biologics Policy
Regulation Health Canada re Patented Medicines (Notice of Compliance) Regulations
Policy or Program Industry Canada re: "Mobilizing Science and Technology to Canada's Advantage".
Legislative Proposal Industry Canada re: Patent Act
Bill or Resolution Industry Canada re: Patent Act
Policy or Program Industry Canada re: Patent Act Guidance (including Patented Medicines Price Review Board Guidance)
Regulation Industry Canada re: Patent Act Regulations (including those on Patented Medicines Price Review Board)
Policy or Program Innovation Strategy;




Date Modified: